Hereditary transthyretin amyloidosis, often called ATTRv amyloidosis, can bring patients to neurology, cardiology or genetics services. Its presentation varies, and a genetic result must be interpreted alongside evidence of organ involvement. The practical task is to establish what protein is involved, whether the condition is hereditary and how it is affecting the patient.
Recognise a variable clinical pattern
Transthyretin amyloidosis involves abnormal protein deposits in tissues. Peripheral neuropathy may cause sensory loss or weakness, while autonomic involvement can affect blood pressure, bowel function and urination. Cardiac, ocular and renal manifestations can also occur. Neuropathic and cardiac presentations overlap; these labels should not imply that disease is restricted to one organ system. MedlinePlus Genetics describes the clinical spectrum.
A useful assessment therefore looks beyond the presenting complaint. Neuropathy accompanied by autonomic symptoms or cardiac findings warrants a broader explanation than neuropathy alone. However, these findings are not specific: symptoms of amyloidosis overlap with many other conditions. Their presence raises a diagnostic question rather than resolving it. The NHS overview explains this diagnostic overlap.
Separate amyloid type from inherited cause
Amyloidosis is a group of conditions. AL amyloidosis involves immunoglobulin light chains, whereas ATTR involves transthyretin. ATTR itself includes hereditary and wild-type disease. Wild-type ATTR involves protein with a normal sequence and should not be described as an inherited TTR disorder. These distinctions matter because the investigations and treatment pathways differ. The NHS summarises the principal amyloidosis types.
Clinical evaluation may include blood and urine studies, cardiac imaging and tissue examination. Genetic testing addresses the hereditary component; it does not replace assessment of the organs involved. A report should make clear which question each investigation has answered, rather than compressing the entire work-up into the single label “amyloidosis.” See the NHS description of diagnostic investigations.
A monoclonal protein does not settle amyloid typing
An important pitfall is assuming that a circulating monoclonal protein proves AL amyloidosis. NHS genomic guidance cautions against accepting low or moderate levels of clonal light chains or intact immunoglobulin as proof without appropriate tissue evidence. When findings remain unresolved, specialist protein analysis and genomic testing may help clarify the diagnosis. GeNotes discusses amyloid typing and diagnostic uncertainty.
Interpret inheritance without predicting a fixed future
In hereditary ATTR, disease-associated TTR variants alter the protein and favour formation of amyloid fibrils. Inheritance is autosomal dominant, but penetrance is incomplete: some people with a disease-associated variant never develop clinical amyloidosis. A positive genetic finding therefore needs a different explanation in an asymptomatic relative than in someone with compatible organ disease. MedlinePlus explains the molecular mechanism and incomplete penetrance.
For a heterozygous parent, each child has a 50% chance of inheriting the variant. That probability does not specify whether symptoms will develop, their timing or their severity. Age at onset and organ involvement can vary within families. An apparently negative family history also cannot exclude hereditary disease. These uncertainties belong in counselling and in the clinical record. GeNotes outlines inheritance and variable expression.
Distinguish established treatment from further research
ATTR-directed treatment is established clinical care for defined indications. For example, the US prescribing information for vutrisiran, a transthyretin-directed small interfering RNA, includes adult hereditary ATTR polyneuropathy and adult wild-type or hereditary ATTR cardiomyopathy. The cardiac indication specifies reduction of cardiovascular mortality, cardiovascular hospitalisations and urgent heart-failure visits. This is a concrete example, not a complete treatment comparison. The prescribing information defines these indications.
Those indications concern clinical disease; they do not establish benefit from treating every asymptomatic variant carrier. Likewise, evidence from one organ phenotype should not automatically be extended to another population. Such extensions require research evidence. Safety assessment also remains essential: the label identifies reduced serum vitamin A as a treatment concern and states that paediatric safety and effectiveness have not been established. The label details these clinical limits.
A useful clinical summary records the evidence for amyloid type, the exact genetic finding, documented organ involvement and remaining uncertainty. Keeping these elements explicit makes subsequent specialist review and family discussions easier to interpret.